曲美他嗪联合β受体阻滞剂治疗急性心肌梗死并发心力衰竭临床研究  

Clinical study of trimetazidine combined with beta-receptor blockers in the treatment of acute myocardial infarction complicated with heart failure

作　　者：刘树理[1] 潘景业[2] 缪心军[1] 

机构地区：[1]温州医科大学定理临床学院(温州市中心医院),浙江省温州325000 [2]温州医科大学附属第一医院

出　　处：《现代实用医学》2016年第11期1417-1419,共3页Modern Practical Medicine

基　　金：温州市科技计划项目(Y20140264)

摘　　要：目的探讨曲美他嗪联合β受体阻滞剂治疗急性心肌梗死(AMI)并发心力衰竭的临床疗效。方法收集AMI并发心力衰竭患者110例,分为对照组和观察组,各55例,在常规对症干预基础上分别给予β受体阻滞剂单用和与曲美他嗪联用治疗;比较两组临床疗效、治疗前后超声心动图指标、血浆B型脑钠肽(BNP),C反应蛋白(CRP)白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平及不良反应发生率。结果两组有效率差异有统计学意义(P<0.05);观察组治疗后超声心动图指标水平均显著优于对照组(均P<0.05);观察组治疗后血浆BNP,CRP、IL-6及TNF-α水平均显著优于对照组(均P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论曲美他嗪联合β受体阻滞剂治疗AMI并发心力衰竭可有效提高心脏舒缩功能,改善相关实验室指标,且未增加不良反应发生率。To investigate the clinical effects and safety of trimetazidine combined with beta-receptor blockers in the treatment of acute myocardial infarction （AMI ）complicated with heart failure.Methods One hundred and ten patients with AMI complicated with heart failure were chosen and randomly divided into two groups, and control group （55 patients） was treated with beta-receptor blockers alone and observation group （55 patients） with trimetazidine combined with beta-receptor blockers on the basis o f conventional symptomatic intervention. The clinical efficacy, the levels of echocardiographic parameters, plasma brain natriuretic peptide （BNP）, C-reactive protein （CRP）, interleukin-6 （ IL-6） and tumor necrosis factor-a （TNF-a ） before and after treatment and adverse reaction incidence of both groups were compared. Results The clinical efficacy of ob-servation group was significantly better than that of control group （P 〈 0.05）. The level o f echocardiographic parameters after treatment of observation group was significantly better than that of control group （P 〈 0.05）. The levels of plasma BNP, CRP, IL-6 and TNF-a after treatment of observation group were significantly better than those of control group （allP 〈 0.05）. There was no significant difference in the adverse reaction incidence between two groups （P 〉 0.05）. Conclusions Trimetazidine combined with beta-receptor blockers in the treat-ment of AMI complicated with heart failure can efficiently higher the cardiac systolic function and improve the relevant laboratory indicators without increasing the adverse reactions risk.

关 键 词：曲美他嗪 Β受体阻滞剂 心肌梗塞 急性 心力衰竭 

分 类 号：R542.2[医药卫生—心血管疾病]